These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
546 related articles for article (PubMed ID: 20299189)
1. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P; Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Gil-Nagel A; Lopes-Lima J; Almeida L; Maia J; Soares-da-Silva P; Acta Neurol Scand; 2009 Nov; 120(5):281-7. PubMed ID: 19832771 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Gil-Nagel A; Elger C; Ben-Menachem E; Halász P; Lopes-Lima J; Gabbai AA; Nunes T; Falcão A; Almeida L; da-Silva PS Epilepsia; 2013 Jan; 54(1):98-107. PubMed ID: 22882018 [TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333 [TBL] [Abstract][Full Text] [Related]
6. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P; Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898 [TBL] [Abstract][Full Text] [Related]
7. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Elger C; Bialer M; Cramer JA; Maia J; Almeida L; Soares-da-Silva P Epilepsia; 2007 Mar; 48(3):497-504. PubMed ID: 17319919 [TBL] [Abstract][Full Text] [Related]
8. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Brodie MJ; Duncan R; Vespignani H; Solyom A; Bitenskyy V; Lucas C Epilepsia; 2005 Jan; 46(1):31-41. PubMed ID: 15660766 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857 [TBL] [Abstract][Full Text] [Related]
10. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM; Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886 [TBL] [Abstract][Full Text] [Related]
11. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175 [TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Husain A; Chung S; Faught E; Isojarvi J; McShea C; Doty P Epilepsia; 2012 Mar; 53(3):521-8. PubMed ID: 22372628 [TBL] [Abstract][Full Text] [Related]
13. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Halász P; Kälviäinen R; Mazurkiewicz-Beldzińska M; Rosenow F; Doty P; Hebert D; Sullivan T; Epilepsia; 2009 Mar; 50(3):443-53. PubMed ID: 19183227 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Brodie MJ; Lerche H; Gil-Nagel A; Elger C; Hall S; Shin P; Nohria V; Mansbach H; Neurology; 2010 Nov; 75(20):1817-24. PubMed ID: 20944074 [TBL] [Abstract][Full Text] [Related]
17. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Brodie MJ; Rosenfeld WE; Vazquez B; Sachdeo R; Perdomo C; Mann A; Arroyo S Epilepsia; 2009 Aug; 50(8):1899-909. PubMed ID: 19490053 [TBL] [Abstract][Full Text] [Related]
18. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Elger CE; Stefan H; Mann A; Narurkar M; Sun Y; Perdomo C Epilepsy Res; 2010 Feb; 88(2-3):255-63. PubMed ID: 20061123 [TBL] [Abstract][Full Text] [Related]
19. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Shinnar S; Pellock JM; Conry JA Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174 [TBL] [Abstract][Full Text] [Related]